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Abstract
Background: The practice of breast cancer diagnosis and treatment in China varies to that in western developed
countries. With the unavailability of radioactive tracer technique for sentinel lymph nodes biopsy (SLNB), using blue
dye alone has been the only option in China. Also, the diagnosis of breast malignant tumor in most Chinese
centres heavily relies on intraoperative instant frozen histology which is normally followed by sentinel lymph nodes
mapping, SLNB and the potential breast and axillary operations in one consecutive session. This practice appears to
cause a high false negative rate (FNR) for SLNB. The present study aimed to investigate the impact of the current
practice in China on the accuracy of SLNB, and whether partial axillary lymph node dissection (PALND), dissection
of lymph nodes inferior to the intercostobrachial nerve (ICBN), was a good complementary procedure following
SLNB using blue dye.
Methods: 289 patients with clinically node-negative breast cancer were identified and recruited. Tumorectomy,
intraoperative instant frozen histological diagnosis, SLNB using methylene blue dye, and PALND or complete
axillary node dissection (ALND) were performed in one consecutive operative session. The choice of SLNB only,
SLNB followed by PALND or by ALND was based on the pre-determined protocol and preoperative choice by the
patient. Clinical parameters were analyzed and survival analysis was performed.
Results: 37 % patients with clinically negative nodes were found nodes positive. 59 patients with positive SLN
underwent ALND, including 47 patients with up to two positive nodes which were all located inferior to the
ICBN. 9 patients had failed SLNB and underwent PALND. Among them, 3 (33.3 %) patients were found to have
one metastatic node. 149 patients showed negative SLNB but chose PALND. Among them, 30 (20.1 %), 14 (9.4)
and 1 (0.7 %) patients were found to have one, two and three metastatic node(s), respectively. PALND detected
48 (30.4 %) patients who had either failed SLNB or negative SLNB to have additional positive nodes. All the
patients with up to two positive nodes had their nodes located inferior to the ICBN. The FNR of SLNB was 43 %.
The accuracy rate was 58 %. The follow-up ranged 12–33 months. The incidence of lymphedema for SLNB,
PALND, and ALND was 0 %, 0 %, and 25.4 %, respectively (P < 0.005). The disease-free survivals for SLNB, PALND,
and ALND groups were 95.8 %, 96.8 %, and 94.9 %, respectively (p > 0.05).
Conclusions: Under the circumstances of current practice in China, PALND is a good complementary procedure
following SLNB in clinically node-negative breast cancer.
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Background
Since the description of the radical mastectomy for
patients with breast cancer 100 years ago, axillary lymph
node dissection (ALND) has been a necessary part of
the operative procedure [1]. Despite the high incidence
of arm lymphedema after ALND, before the 1970s most
surgeons mainly focused on ensuring patients’ survival
rather than minimising this severe complication [2]. In
1980s, advances in chemotherapy, radiotherapy and
endocrine therapy significantly improved long term sur-
vival [3, 4]. Improving the quality of life for patients with
early-stage breast cancer became an important issue. In
1983, Rosen et al. subdivided the axillary lymph nodes
(ALNs) into three levels according to their location in
relation to the pectoralis minor muscle, and recom-
mended that ALND be carried out from Level I to Level
III in a stepwise manner [5]. In the mid-1990s, sentinel
lymph node biopsy (SLNB) was introduced [6] and
proven to be the best diagnostic modality to accurately
stage axilla and select patients with early-stage breast
cancer who can be spare of unnecessary ALND and its
possible risk of arm lymphedema [7]. The key to SLNB
is to accurately identify sentinel lymph nodes (SLNs). Al-
though different methodologies can be used for SLNB,
the combined technique of blue dye plus radioactive
tracer is significantly superior to blue dye alone tech-
nique in terms of negative predictive value and overall
accuracy for identification of SLNs [7]. Thus, the com-
bined technique of blue dye with radioactive tracer is
generally considered as a gold standard for SLNB.
China is a developing country with considerably un-
even economic development and rural–urban inequities
in healthcare resources across regions. Compared with
western developed countries, the practice of breast can-
cer diagnosis and treatment in China varies remarkably.
With the radioactive tracer technique being applied
mainly in research and not being permitted in clinical
surgeries, using blue dye alone has been the major tech-
nique in large urban medical centres in China where the
majority of rural hospitals are unable to provide SLNB
service [8]. Meanwhile, with an aim to shorten waiting
time and hospital stays to tackle the increasing shortage
in healthcare resources, tumorectomy, intraoperative in-
stant frozen histology diagnosis, the potential SLNs
mapping and SLNB, and axillary lymph node interven-
tion are normally performed in one consecutive opera-
tive session in most medical centres. Low preoperative
biopsy rate means that the primary diagnosis of breast
cancer relies heavily on intraoperative instant frozen
histology. However, the practice of the performing
tumorectomy and instant frozen histology prior to SLNs
mapping leads to a potentially high false negative rate
(FNR) for SLNB because of the effect of open incision
on lymphatic drainage. As a result, it has been one of
the major goals for the Chinese breast cancer experts to
find an easier and more effective method addressing
SLN intervention under such circumstances specific to
China.
Since 2007, our surgical team has been investigating
the metastasis patterns of lymph nodes and distribution
of ALNs in relation to the intercostobrachial nerves
(ICBNs), which resulted in two publications. We found
that ICBN can be an anatomic marker dividing axillary
spaces into superior and inferior parts [9]. Short-term
follow-up showed that partial axillary lymph node dis-
section (PALND), dissection of lymph nodes inferior to
the ICBNs traced by dye, was a good supplementary pro-
cedure to follow SLNB. PALND effectively assessed the
status of ALNs and prevented lymphedema after surgery
[10]. The long term effects of PALND, however, still re-
main unknown. The present study aimed to investigate
the impact of the current practice in China on the accur-
acy of SLNB, and whether PALND is a good comple-
mentary procedure following SLNB using blue dye. Data
from patients with clinically node-negative breast cancer
were analyzed to determine the FNR and accuracy rate
for SLNB and nodes dissection in relation to ICBN. Sur-
vival analysis was also conducted in patients who under-




Between July 2009 and April 2012, a total of 475 patients
with suspected malignant breast tumor by preoperative
imaging were investigated and approached for consent
to participate in the study at the Shengjing Hospital of
China Medical University. None of the patients under-
went preoperative biopsy. Among them, 289 patients
with clinically node-negative breast cancer were identi-
fied by intraoperative frozen instant histology and subse-
quently recruited in this study. Inclusive criteria were:
(1) clinically node-negative breast cancer, defined as
negative on preoperative axillary palpation, ultra sound
examination and CT scan with contrast; (2) no previous
history of breast cancer or other malignancies; (3) no
neoadjuvant therapy; (4) no pregnancy. Those who had a
benign tumor and those who did not meet the above cri-
teria were excluded from the study.
Study protocols
In the preoperative consultation with the patient and
their family, the surgeons provided thorough education
and explanation which included the introduction of
surgical procedures, study protocols, possible options to
choose from if the tumor was proved to be malignant by
intraoperative instant frozen histology, significance of
SLNB, advantages and disadvantages of blue dye
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technique and our ongoing study on PALND. The pa-
tient was informed that although blue dye alone is con-
sidered acceptable for staging and prognostication based
on the current guidelines, it may cause false negative re-
sult which potentially misses out positive nodes; PALND
following SLNB may offset the disadvantage but its
long-term complications are unclear. Patients were given
enough time to make voluntary decision. An informed
consent form and the preference of choice on surgical
procedures if the tumor was malignant were obtained.
All surgical procedures were performed by the same
surgical team. The study was approved by the ethics
committee of Shengjing Hospital of China Medical
University.
All the procedures were done in one consecutive op-
erative session. Firstly, tumorectomy was performed
through open surgery and the tumor was examined by
intraoperative instant frozen histology analysis. SLN
mapping and SLNB were followed if the tumor was
proved to be malignant. 2–3 sections were examined for
each node investigated by instant frozen histology. If
SLNB failed (no blue staining nodes identified), PALND
was subsequently performed. If SLNB succeeded and
SLN was negative for cancer cells by instant frozen hist-
ology, either PALND or no axillary intervention (SLNB
only) was followed based on the patient’s preoperative
choice. If SLNB succeeded and SLNs showed positive,
the patients were offered ALND (Fig. 1).
Operative techniques
Once the malignant tumor was diagnosed by instant fro-
zen histology, SLNB mapping using methylene blue dye
(3–4 ml, 25 mg/ml) was immediately followed as de-
scribed previously [11]. Briefly, 2/3 of the dye dose was
injected into the tumor bed and 1/3 into areola of the
breast if the tumor was located in the outer quadrant; if
the tumor was located in the inner quadrant, 1/3 of the
dose was injected into the tumor bed and 2/3 into areola
of the breast. The breast and axillary operations were
then performed following 10–15 min massage. We
understood that the protocol of performing SLN map-
ping after tumorectomy would significantly affect the ac-
curacy of SLNB, depending on the location and size of
the open incision. However, because this was the com-
mon practice in most centres (including ours) in China,
one of the aims of the study was to investigate its impact
on the accuracy of SLNB.
For the axillary operation, the ICBN was exposed com-
pletely in the axillary space. All the anatomic locations
of soft tissues and lymph nodes removed in relation to
Fig. 1 Axillary Intervention in 289 Patients with Early Stage Breast Cancer. Illustration: Firstly, 475 patients with suspected malignant breast tumor
by preoperative imaging were investigated and approached for consent to participate in the study at the Shengjing Hospital of China Medical
University. Among them, 289 patients with clinically node-negative breast cancer were identified by intraoperative frozen instant histology and
subsequently recruited in this study. Then, 289 patients underwent SLNB. 9 patients had failed SLNB who underwent PALND. 280 patients had
successful SLNB, among whom 59 patients showed positive SLN and underwent ALND; 221 patients showed negative SLN, 149 of them chose
PALND and 72 of them opted for no axillary intervention (end)
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ICBN were recorded. The lymph nodes adjoining the
ICBN belong to the lower lymph nodes. The long thor-
acic and thoracodorsal nerves were identified and pre-
served during the operation [Fig. 2]. The anatomical
variations of ICBN were explored during the procedure,
and recorded if any was identified. PALND technique in-
volved removal of all the axillary fat pad and lymph
nodes inferior to the ICBN. Drainage tube with the same
calibre was placed in the axillary space at the end of the
operation. All the nodes harvested were postoperatively
examined for metastasis by histology.
Clinical assessment
When the drainage volume was less than 10 ml per
24 h, the tube was removed, and the extubation time
and the total volume of drainage were recorded. Body
mass index (BMI) and arm circumference at the point
of 10 cm proximal to the medial epicondyle were mea-
sured before surgery and again one year after surgery.
The changes in ipsilateral upper extremity circumfer-
ence, corrected for any change in the contralateral
upper extremity, were calculated using the increase in
arm circumference based on the formula introduced by
McLaughlin et al. [12]. Severe lymphedema was diag-
nosed if the increase in arm circumference was greater
than or equal to 2 cm during the follow-up period, and
mild lymphedema was defined as increase less than
2 cm. We observed substantial weigh gains in many
patients after surgery which unexpectedly altered the
arm circumference, making this objective tool less ac-
curate. Thus, a subjective method assessing long-term
arm lymphedema was proposed and applied: if the pa-
tient felt their ipsilateral arms were as good as the
contralateral arm, they were defined as no lymphedema;
if the patient did not feel that their ipsilateral arms
were as good as the contralateral arms but did not
affect their daily life, they were defined as mild lymph-
edema; if their arm lymphedema affect their daily life,
they were defined as severe lymphedema.
The collected clinical parameters included: number of
nodes, postoperative extubation time, axillary drainage
volume, changes in BMI and arm circumference, and
other conventional indicators.
Statistical analysis
All statistical analyses were carried out using SPSS soft-
ware (version 17.0 for Windows, Chicago, Illinois,
USA). The correlation analyses among groups and the
various biological factors were examined using the Chi-
Square test or analysis of variance (ANOVA). For
survival analysis, disease-free survival (DFS) were deter-
mined using the Kaplan–Meier curves. The log-rank
test was used to compare survival differences among
the groups. P value < 0.05 was considered statistically
significant.
Fig. 2 Part of axillary lymph node dissection. Illustration: Part of axillary lymph node dissection (PALND) is bordered by intercostobrachial nerve
(ICBN) on the upper margin, by the long thoracic nerve on the median margin, and by the thoracodorsal nerve on the posterior margin. The
ICBN is revealed completely in the axillary space, and the lymph nodes adjoining the ICBN belong to the lower lymph nodes
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Results
Patient distribution in groups with different intervention
Of the total of 289 recruited patients, no blue-staining
SLN was identified in 9 patients who subsequently under-
went PALND; therefore the success rate of dye-tracing
was 96.9 % (280/289). In 280 patients with successful
SLNB, 221 (78.9 %) patients had negative SLN, among
whom 149 patients chose PALND and 72 patients opted
for no axillary intervention. 59 patients were found SLN
positive and underwent ALND as a result. Altogether, 107
out of 289 (37 %) patients with clinically negative nodes
were found nodes positive by histology [Fig. 1].
Characteristics of patients
As shown in Table 1, no differences among groups were
found in age, menopause, family history, quadrant distri-
bution, operation type, tumour diameter, pathological
types, histological grades, cancer thrombosis, biomarkers
(PgR, Ki67 and P53) and targeted therapy (p > 0.05).
PALND and ALND had higher node metastasis rates
(30.4 % and 100 % respectively) compared with the
SLNB group (0 %) (p < 0.005). The positive Estrogen re-
ceptor rates were higher in the SLNB (61.1 %) and
PALND (56.3 %) groups than in the ALND group
(28.8 %) (p < 0.005). The ALND group showed higher
positive Her2 rate, higher IIB stage rate, more chemo-
therapy cycles and higher radiotherapy rate than its two
counterparts (p < 0.005).
Clinical outcomes
The number of removed axillary lymph nodes in the
ALND group (22.83 ± 5.61) was greater than in the
SLNB (3.42 ± 1.45) and PALND (13.53 ± 2.29) groups
(p < 0.005). Also, the ALND group presented longer
postoperative extubation time, greater total drainage vol-
ume, and greater increase in BMI and arm circumfer-
ence compared with its two counterparts (p < 0.005)
(Table 2). Severe lymphedema evaluated using the abso-
lute changes in arm circumference was not found in the
SLNB and PALND groups, 25.4 % severe lymphedema
was noted in the ALND group (p < 0.005). When using
the subjective criteria, severe lymphedema was not re-
ported by any patients in the SLNB and PALND groups,
but reported by 30.5 % of patients in the ALND group
(p < 0.005) (Table 2).
Anatomic location of blue staining SLNs
All the methylene blue staining SLNs were found around
or inferior to the ICBN in 286/289 (99 %) patients
[Fig. 3]. For the anatomical variations of ICBN, we only
found one case of ICBN defect. According to a previous
study, the pectoralis minor branch of thoracoacromial
artery (PMBTA) can substitute ICBN as anatomic
landmark [8].
Distribution of metastatic nodes in patients underwent
ALND
As mentioned, 59 patients with positive SLN underwent
ALND. Among them, there were 56 patients whose
metastatic axillary nodes were all located inferior to the
ICBN, including all the patients with one or two meta-
static nodes (n = 47) and 9 patients with three metastatic
nodes. Three patients were found to have metastatic
nodes both inferior and superior the ICBN (2 patients
with three metastatic nodes and 1 patient with four
metastatic nodes) (Table 3).
Distribution of metastatic nodes in patients underwent
PALND
As stated, 9 patients had failed SLNB and underwent
PALND. Among them, 6 (66.7 %) patients were found
no metastatic nodes and 3 (33.3 %) patients were found
to have one metastatic node postoperatively. Meanwhile,
149 patients showed negative SLNB but chose PALND.
Among them, 104 (69.8 %) patients were proved node
metastasis free. However, 30 (20.1 %), 14 (9.4) and 1
(0.7 %) patients were found to have one, two and three
metastatic node(s), respectively (Table 4). Putting to-
gether, PALND detected 48 (30.4 %) out of 158 patients
who had either failed SLNB or negative SLNB to have
additional positive axillary nodes.
FNR of SLNB
If the nine patients with failed SLNB were not included
in the analysis, the FNR of SLNB using blue dye in the
present study was 43 % (45/104). The accuracy rate was
58 % (163/280) (Table 4).
Outcomes of follow-up
The follow-up time ranged from 12 to 33 months in
each group with median 24 months, 20.5 months and
22 months for SLNB, PALND and ALND, respectively
(p > 0.05). The actual DFS of SLNB, PALND, and ALND
groups were 95.8 %, 96.8 %, and 94.9 %, respectively
(p > 0.05), and the median DFS time was 30 months in
each group [Table 5]. No differences were observed
among groups in the curves for DFS [Fig. 4]. There was
no difference in local recurrence among groups.
Discussion
As preservation of the ICBNs does not affect patient
survival but significantly ameliorates the sensory deficit
and other long-term symptoms [13], this procedure po-
tentially provides a new anatomic landmark in axillary
lymph nodes dissection. In our previous study investigat-
ing the anatomic localization of SLNs in relation to the
ICBN, we found that the majority of SLNs were located
inferior to the ICBN using a dye-tracer technique, and
axillary lymph nodes metastases progress from the
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Table 1 Characteristics of patients and treatments in all groups
Parameters SLNB PALND ALND Statistics P
(n = 72) (n = 158) (n = 59) (F or X2)
Age 0.391 0.677
Mean, y 51.68 ± 9.68 52.06 ± 9.90 53.15 ± 10.01
Range, y 29 ~ 73 25 ~ 82 35 ~ 80
Menopause 1.305 0.521
Yes 37 (51.4 %) 73 (46.2 %) 32 (54.2 %)
No 35 (48.6 %) 85 (53.8 %) 27 (45.8 %)
Family History 1.412 0.494
No 61 (84.7 %) 142 (90.0 %) 53 (89.8 %)
Cancer (Including BC) 11 (15.3 %) 16 (10.0 %) 6 (10.2 %)
Quadrant 10.416 0.237
Areolar 5 (6.9 %) 18 (11.4 %) 8 (13.6 %)
Outer upper 45 (62.5 %) 83 (52.5 %) 26 (44.1 %)
Outer lower 17 (23.6 %) 32 (20.3 %) 12 (20.3 %)
Inner lower 3 (4.2 %) 13 (8.2 %) 9 (15.2 %)
Inner upper 2 (2.8 %) 12 (7.6 %) 4 (6.8 %)
Operation 6.913 0.141
Mastectomy 54 (75.0 %) 129 (81.6 %) 42 (71.2 %)
Tumorectomy 13 (18.1 %) 27 (17.1 %) 14 (23.7 %)
Breast Reconstruction 5 (6.9 %) 2 (1.3 %) 3 (5.1 %)
Diameter 2.61 ± 1.04 2.50 ± 1.00 2.67 ± 1.00 0.686 0.504
Pathological Types 12.749 0.546
IDC 47 (65.3 %) 96 (60.8 %) 40 (67.8 %)
ILC 4 (5.5 %) 13 (8.2 %) 2 (3.4 %)
DCIS 9 (12.5 %) 24 (15.2 %) 5 (8.5 %)
Other Types 12 (16.7 %) 25 (15.8 %) 12 (20.3 %)
Histological Grade 7.125 0.129
I 15 (20.8 %) 43 (27.2 %) 23 (39.0 %)
II 36 (50.0 %) 64 (40.5 %) 24 (40.7 %)
III 21 (29.2 %) 51 (32.3 %) 12 (20.3 %)
Node Metastasis 145.677 0.000
No 72 (100.0 %) 110 (69.6 %) 0 (0.0 %)
Yes 0 (0.0 %) 48 (30.4 %) 59 (100.0 %)
Cancer Thrombosis 3.034 0.219
No 47 (65.3 %) 88 (55.7 %) 30 (50.8 %)
Yes 25 (34.7 %) 70 (44.3 %) 29 (49.2 %)
Estrogen Receptor 16.285 0.000
Negative 28 (38.9 %) 69 (43.7 %) 42 (71.2 %)
Positive 44 (61.1 %) 89 (56.3 %) 17 (28.8 %)
Progesterone Receptor 5.770 0.056
Negative 40 (55.6 %) 88 (55.7 %) 43 (72.9 %)
Positive 32 (44.4 %) 70 (44.3 %) 16 (27.1 %)
Her2 17.787 0.000
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Table 1 Characteristics of patients and treatments in all groups (Continued)
Negative 62 (86.1 %) 137 (86.7 %) 37 (62.7 %)
Positive 10 (13.9 %) 21 (13.3 %) 22 (37.3 %)
Ki67 0.010 0.995
Negative 53 (73.6 %) 116 (73.4 %) 43 (72.9 %)
Positive 19 (26.4 %) 42 (26.6 %) 16 (27.1 %)
P53 1.497 0.473
Negative 41 (56.9 %) 77 (48.7 %) 32 (54.2 %)
Positive 31 (43.1 %) 81 (51.3 %) 27 (45.8 %)
Clinical Stage 92.884 0.000
0 9 (12.5 %) 14 (8.9 %) 0 (0.0 %)
I 22 (30.6 %) 49 (31.0 %) 0 (0.0 %)
IIA 41 (56.9 %) 51 (32.3 %) 16 (27.1 %)
IIB 0 (0.0 %) 44 (27.8 %) 43 (72.9 %)
Clinicopathological Subtypes 32.593 0.000
Luminal A 37 (51.4 %) 76 (48.1 %) 16 (27.1 %)
Luminal B Ki67+ 13 (18.1 %) 27 (17.1 %) 7 (11.9 %)
Luminal B Her2+ 6 (8.3 %) 9 (5.7 %) 3 (5.1 %)
Her2 Over-Expression 4 (5.5 %) 12 (7.6 %) 19 (32.2 %)
TNBC 12 (16.7 %) 34 (21.5 %) 14 (23.7 %)
Chemotherapy Protocols 84.222 0.000
No 6 (8.3 %) 15 (9.5 %) 5 (8.5 %)
CMF 1 (1.4 %) 8 (5.1 %) 0 (0.0 %)
CAF or AC 20 (27.8 %) 26 (16.5 %) 0 (0.0 %)
CEF or EC 18 (25.0 %) 36 (22.8 %) 0 (0.0 %)
TC or TP 23 (31.9 %) 37 (23.3 %) 14 (23.7 %)
TAC or AC-T 4 (5.6 %) 36 (22.8 %) 40 (67.8 %)
Chemotherapy Cycle 72.874 0.000
0 6 (8.3 %) 15 (9.5 %) 5 (8.5 %)
4 19 (26.4 %) 26 (16.5 %) 0 (0.0 %)
6 43 (59.7 %) 81 (51.2 %) 14 (23.7 %)
8 4 (5.6 %) 36 (22.8 %) 40 (67.8 %)
Targeted Therapy 4.201 0.122
No 71 (98.6 %) 152 (96.2 %) 54 (91.5 %)
Yes 1 (1.4 %) 6 (3.8 %) 5 (8.5 %)
Radiotherapy 26.425 0.000
No 54 (75.0 %) 100 (63.3 %) 19 (32.2 %)
Yes 18 (25.0 %) 58 (36.7 %) 40 (67.8 %)
Endocrine Therapy 20.478 0.002
No 16 (22.1 %) 46 (29.1 %) 33 (55.9 %)
TAM 22 (30.6 %) 49 (31.0 %) 9 (15.3 %)
LHRH 12 (16.7 %) 17 (10.8 %) 5 (8.5 %)
AI 22 (30.6 %) 46 (29.1 %) 12 (20.3 %)
SLNB sentinel lymph node biopsy, PALND partial axillary lymph node dissection, ALND axillary lymph node dissection, BC breast cancer, IDC invasive ductal
carcinoma, ILC invasive lobular carcinoma, DCIS ductal carcinoma in situ, TNBC triple negative breast cancer, CMF cyclophosphamide + methotrexate +
5fluorouracil, CAF cyclophosphamide + doxorubicin + 5fluorouracil, AC doxorubicin + cyclophosphamide, CEF cyclophosphamide + epirubicin + 5fluorouracil,
EC epirubicin + cyclophosphamide, TC docetaxel + cyclophosphamide, TP docetaxel + cisplatin, TAC docetaxel + doxorubicin + cyclophosphamide, AC-T
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inferior to the superior axillary as divided by ICBN [9].
This is similar to the findings by Clough et al. who discov-
ered that nearly 89 % SLNs were inferior to the ICBN and
few were located superior to ICBN and at the outside of
the subscapular artery when traced by the combined
method [14]. A recent study demonstrated that the node
draining the arm lymph vessels was localized in the lateral
pillar of the axillary, and was always found superior to or
at the level of the second ICBN [15]. These findings indi-
cate that the localization of nodes draining the breast and
the arm lymphatic vessels is not overlapping and is largely
divided by ICBN. Theoretically, postoperative arm lymph-
edema is preventable if the tissue and nodes superior to
ICBN are preserved. PALND, which only involves dissec-
tion of nodes inferior to ICBN, should have similar lymph-
edema occurrence rate with SLNB but lower rate than
ALND. In the present study, no postoperative severe arm
lymphedema was found after one year follow-up in the
SLNB and PALND groups with over 15 % of severe
lymphedema in the ALND group, suggesting PALND has
the same protective effect as SLNB on arm lymphedema
and is superior to ALND because the lymphatic drainage
of the arm was preserved. The high level of chemotherapy,
later clinical stage, and the poorer clinicopathological sub-
types in the ALND group may have also contributed to
the lymphedema observed in this group.
We carried out survival analysis according to the
types of axillary intervention. There was no difference
among the SLNB, PALND and ALND groups in DFS
with a zero recurrence rate in all groups. Patients in the
ALND group might have benefited from chemotherapy
and radiotherapy. Our findings are consistent with a
study by Kodama et al. who compared overall 5-year
survival rates in patients undergoing PALND and his-
torical controls undergoing conventional dissection
[16]. Thus, there is sufficient evidence to suggest that
PALND can significantly prevent arm lymphedema with
a satisfying DFS.
Blue dye is so far the first choice for SLNB in China
because it is cheap, safe without the need for nuclear
medicine department and gamma probes. However, al-
though blue dye alone technique is generally considered
as a valid and acceptable tool to assess axillary nodes
status and staging [17], there is growing evidence sug-
gesting the combined technique of blue dye plus radio-
active tracer is more superior. In a randomized study by
Radovanovic et al., the false rate of blue dye was 17.6 %
and accuracy was 68 % [7]. Other studies in the litera-
ture showed the similar false-negative rates for the blue
dye alone method which were generally higher than the
recommended 5 % rate [18, 19]. The combined blue dye
and radioactive tracer had a significantly lower FNR
doxorubicin + cyclophosphamide follow docetaxel, TAM tamoxifen, LHRH luteinising-hormone-releasing hormone, AI aromatase inhibitors. All nodes would be
histopathological diagnosed to detect macrometastasis
Table 2 Clinical outcomes in groups with different axillary intervention
Parameters SLNB PALND ALND Statistics P
(n = 72) (n = 158) (n = 59) (F or X2)
Number of LN 3.42 ± 1.45 13.53 ± 2.29 22.83 ± 5.61 631.709 0.000
Postoperative Extubation time (day) 3.49 ± 1.09 4.87 ± 1.43 10.19 ± 2.73 280.783 0.000
Drainage Volume (ml) 284.51 ± 73.37 492.80 ± 75.51 784.75 ± 147.38 458.521 0.000
BMI Preoperative 23.63 ± 3.49 23.48 ± 3.16 23.83 ± 3.69 0.248 0.781
BMI Postoperative 23.85 ± 3.41 23.72 ± 3.16 24.69 ± 3.68 1.882 0.154
△BMI 0.20 ± 0.27 0.24 ± 0.15 0.86 ± 0.63 85.318 0.000
Circumference Preoperative(cm) 24.81 ± 2.61 24.84 ± 2.62 24.84 ± 3.05 0.004 0.996
Circumference Postoperative(cm) 25.05 ± 2.56 25.36 ± 2.60 26.29 ± 3.19 3.682 0.026
△Circumference(cm) 0.26 ± 0.43 0.52 ± 0.30 1.45 ± 0.77 118.540 0.000
Lymphedema by Circumference 118.551 0.000
No 64(88.9 %) 77(48.7 %) 8(13.6 %)
Mild (<2 cm) 8(11.1 %) 81(51.3 %) 36(61.0 %)
Severe (△ ≥ 2 cm) 0(0 %) 0(0 %) 15(25.4 %)
Subjective Lymphedema 105.562 0.000
No 70(97.2 %) 152(96.2 %) 28(47.5 %)
Mild 2(2.8 %) 6(3.8 %) 13(22.0 %)
Severe 0(0 %) 0(0 %) 18(30.5 %)
SLNB sentinel lymph node biopsy, PALND partial axillary lymph node dissection, ALND axillary lymph node dissection
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(4.5 %) with higher accuracy [7]. In the present study,
the FNR of blue dye technique was as high as 43 % and
the accuracy rate was only 58 %, which appeared to be
unexpected and unacceptable. We believe that the prac-
tice of performing SLN mapping/SLNB after tumorectoy
is largely responsible for the high FNR and low accuracy
rate as open incision and the tumor removal procedure
are potentially destroy breast lymphatic network, thus
reduce breast lymphatic drainage towards axilla. The
lack of other intensive node exploration technique (e.g.
continuous multiple sections and lymph node imprint)
in the present study may have also been a contributor.
Different from western countries where malignance of a
tumor is determined by preoperative biopsy and surgical
plan is normally determined preoperatively, such prac-
tice is common in China where malignance of a tumor
is largely identified by intraoperative instant frozen hist-
ology and the therapeutic plan is determined intraopera-
tively. With unknown biological behaviour of a tumor
and uncertain time frame before the result of intraopera-
tive frozen histology was available, it appeared inappro-
priate to perform SLNB prior to tumorectomy. Our
study showed an unacceptably higher FNR using blue
dye alone under such circumstances.
We found that 48 (30.4 %) patients who showed either
failed SLNB (33.3 %) or negative SLNB (30.2 %) using
blue dye were found additional positive nodes by
PALND. These data demonstrated that there may be an
over 30 % chance of leaving behind positive nodes for
those with failed or negative SLNB using blue dye alone.
In a country where blue dye is the only option for SLNB
and intraoperative instant frozen histology is the major
method for primary diagnosis of breast cancer, PALND
can be considered as a good complementary procedure
to SLNB in patients with clinically-negative node breast
cancer. Our findings are in keeping with an Indian study
Fig. 3 Sentinel lymph nodes located inferior to the intercostobrachial nerve. Illustration: SLN mostly located under the intercostalbrachial
nerve (ICBN)
Table 3 Anatomic location of metastatic nodes in patients
underwent ALND
Number of LNM Under the ICBN Above the ICBN Patients
1 + - 16
2 + - 31
3 + - 9
+ + 2
4 + + 1
LNM lymph node metastases, ICBN intercostobrachial nerve




































3 0 1 (0.7 %) - 11
(18.6 %)
4 0 0 - 1
(1.7 %)
LNM = lymph node metastases. False negative rate (FNR) of SLNB using blue
dye: 45 % (48/107), accuracy: 55 %
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which showed low axillary sampling is accurate in pre-
dicting axillary nodes status in women with clinically
node negative operable breast cancer [20]. In the light of
the high FNR of SLNB, we are now trialling SLNB prior
to tumorectomy to minimise the effect of open incision
on breast lymphatic drainage in all patients with sus-
pected breast cancer. The FNR and accuracy rate are yet
to be evaluated.
Recently, a presentation and related publications of the
American College of Surgeons Oncology Group (ACO-
SOG) Z0011 have provoked controversy around the world
regarding the need for ALND in patients with SLN-
positive breast cancer [21–23]. It seems that less than or
equal to two positive nodes does not warrant dissection.
In our study, all the patients with less than or equal to two
positive SLNs had all their metastatic nodes located infer-
ior to the ICBN. Only three patients with more than two
metastatic nodes had nodes found superior to the ICBNs.
Therefore, PALND is considered as a way of biopsy for
clinically node-negative breast cancer: if there are two or
fewer positive nodes, then ALND is not necessary and the
PALND is sufficient; if there are more than two positive
nodes, then ALND is necessary. A recent study reported
that for patients with positive nodes who do not undergo
ALND, adjuvant therapy can have the same effect on over-
all survival as the ALND procedure performed on similar
Table 5 Survival analysis according to axillary intervention
Parameters SLNB PALND ALND Statistics P
(n = 72) (n = 158) (n = 59) (F or X2)
Overall Survival 97.2 % 98.1 % 96.6 % 0.445 0.796
Deaths (n) 2 3 2
Median Survival Time (mo) 30.0 30.0 30.0 0.251 0.882
Disease-Free Survival 95.8 % 96.8 % 94.9 % 9.033 0.340
Event (n) 3 5 3
Local Recurrence 0 0 0
Contralateral breast cancer 0 2 0
Bone Metastasis 1 0 0
Lung Metastasis 0 0 1
Multi-Organ 2 3 2
Disease-Free Survival (mo) 30.0 30.0 30.0 0.303 0.860
Follow-Up Time 1.633 0.197
Median (mo) 24.0 20.5 22.0
Range (mo) 12-33 12-33 12-33
SLNB sentinel lymph node biopsy, PALND partial axillary lymph node dissection, ALND axillary lymph node dissection, mo months
Fig. 4 Kaplan-Meier Curves for Disease-free Survival
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node-positive patients [24]. However, the presence of posi-
tive nodes is one of the important factors to be taken into
account when considering radiotherapy and chemother-
apy. Perhaps in the near future we can develop a novel im-
aging technique instead of SLNB for the assessment of
ALNs, we will enter a new era when the axillary surgery is
not necessary. However, at the present time, PALND
could be considered as a procedure complementary to
SLNB in clinically node-negative breast cancer, especially
in China where the combined technique is not available
for SALN detection. This technique is so simple that a
surgeon could easily perform without the need of compli-
cated equipment. In fact, we prefer the name “functional
axillary lymph node dissection (FALND) to PALND, a
term which is coined when SLNs are not located. Our
further investigation is ongoing on the clinical difference
between FALND and ALND when there are two or fewer
positive nodes and the results will be available in the near
future.
In conclusion, there are considerable differences in the
practice of breast cancer diagnosis and treatment between
China and western developed countries. In a country
where blue dye is the only technique for SLNB and intra-
operative SLNB is normally performed after tumorectomy,
the FNR of SLNB is unacceptably high. Under such cir-
cumstances specific to China, axillary node dissection in-
ferior to the ICBN is a good complementary procedure
following SLNB in clinically node-negative breast cancer
because it provides better assessment of nodes status, re-
duces the occurrence rate for postoperative arm lymph-
edema with satisfying long-term disease free survival.
Conclusions
The current practice in China where SLNB is generally
performed after tumorectomy and intraoperative instant
frozen histology reduces the accuracy of SLNB using
blue dye. Under such specific circumstances, PALND is
a good complementary procedure following SLNB in
clinically node-negative breast cancer.
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